Abstract: Objective To study the expression of P53,EGFR,HER-2,and VEGF in gastric carcinoma and its relation with the prognosis of gastric carcinoma patients. Methods One hundred and forty-seven patients with stages I-Ⅳlocal advanced gastric carcinoma who underwent gastrectomy with extended（D2）lymph-node dissection and then received 5-Fu-based adjuvant chemotherapy in our hospital from January 2004 to December 2007 were retrospectively analyzed.Expression of P53,EGFR, HER-2,and VEGF proteins was detected by immunohistochemistry（IHC）,and its relation with clinicopathologic features of gastric carcinoma and survival rate of gastric carcinoma patients was analyzed. Results The positive expression rate of P53,EGFR, HER-2,and VEGF was 41%,17.7%,17.0%,and 55.9%,respectively.The expression of EGFR was positively correlated with that of P53（r=0.306,P＜0.05）,while the expression of VEGF was negatively correlated with that of HER-2（r=-0.2,P＜0.05）.The expression of EGFR,HER-2,and VEGF was not related with the age and gender of gastic carcinoma patients,and tumor location, histological rade,size,stage,thrombi.The expression of P53 was only related to the tumor histological grade（P＜0.05）.Univariate analysis showed that the median disease-free survival time of patients with low and high P53 expression levels was 47 and 24 months,respectively（P＜0.05）,with a total median survival time of 66 and 30 months,respectively（P＜0.05）.Multivariate analysis demonstrated that histological grade,depth of invasion,lymphatic involvement and P53 expression were the independent prognostic factors for the overall survival time of gastric carcinoma patients. Conclusion Detecting the expression of P53,EGFR,HER-2,and VEGF in gastric carcinoma contributes to the prediction of the prognosis of gastric carcinoma patients and selection of adjuvant chemotherapy for priority patients,and provides evidence for the molecular target therapy for gastric carcinoma.